Proximal femoral replacement for non-neoplastic conditions: a systematic review on current outcomes

J Orthop Traumatol. 2022 Mar 29;23(1):18. doi: 10.1186/s10195-022-00632-z.

Abstract

Proximal femoral replacement (PFR) is a well-established treatment for neoplasia of the proximal femur. The use of this surgical technique for non-neoplastic conditions has increased over the years. We carried out a systematic review of the literature to study the indications, complications, and functional results when PFR is used for non-neoplastic conditions. Twenty-seven studies were included in the review with a total of 828 PFRs with a mean follow-up of 50 months (range 1-225 months). The main indications were infection (28%), periprosthetic fracture (27%), aseptic loosening (22%), and fracture (16%). The rate of reoperation was 20.3% overall. The overall revision rate was 15.4%. The main complications were dislocation (10.2%) and infection (7.3%). After 2010, the rates of reoperation (25.5% versus 18.2%), loosening (9.4% versus 3.2%), and dislocation (15.7% versus 7.9%) were lower than before 2010. The 30-day mortality ranged from 0% to 9%. The hip function scores improved post-surgery. In conclusion, the use of PFR in non-neoplastic conditions remains a marginal tool, associated with low direct mortality and high complication rates, but we expect its use to increase in the near future.

Keywords: Hip arthroplasty; Megaprosthesis; Proximal femoral replacement; Revision surgery.

Publication types

  • Systematic Review

MeSH terms

  • Arthroplasty, Replacement, Hip* / adverse effects
  • Arthroplasty, Replacement, Hip* / methods
  • Femur / surgery
  • Hip Prosthesis* / adverse effects
  • Humans
  • Periprosthetic Fractures* / etiology
  • Periprosthetic Fractures* / surgery
  • Prosthesis Failure